These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Ebrahimi N; Herbstritt S; Gold R; Amezcua L; Koren G; Hellwig K Mult Scler; 2015 Feb; 21(2):198-205. PubMed ID: 25159275 [TBL] [Abstract][Full Text] [Related]
24. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Hoevenaren IA; de Vries LC; Rijnders RJ; Lotgering FK Acta Neurol Scand; 2011 Jun; 123(6):430-3. PubMed ID: 21492099 [TBL] [Abstract][Full Text] [Related]
25. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. Thiel S; Litvin N; Haben S; Gold R; Hellwig K J Neurol Neurosurg Psychiatry; 2024 May; 95(6):561-570. PubMed ID: 38124108 [TBL] [Abstract][Full Text] [Related]
26. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Razaz N; Piehl F; Frisell T; Langer-Gould AM; McKay KA; Fink K Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33087582 [TBL] [Abstract][Full Text] [Related]
27. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Demortiere S; Rico A; Maarouf A; Boutiere C; Pelletier J; Audoin B Mult Scler; 2021 Apr; 27(5):712-718. PubMed ID: 32202216 [TBL] [Abstract][Full Text] [Related]
28. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Kohlmann R; Salmen A; Chan A; Knabbe C; Diekmann J; Brockmeyer N; Skaletz-Rorowski A; Michalik C; Gold R; Überla K Mult Scler; 2015 Dec; 21(14):1823-32. PubMed ID: 25828755 [TBL] [Abstract][Full Text] [Related]
29. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Amato MP; Portaccio E; Ghezzi A; Hakiki B; Zipoli V; Martinelli V; Moiola L; Patti F; La Mantia L; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; Di Tommaso V; Paolicelli D; Marrosu MG; Comi G; Pellegrini F; Trojano M; Neurology; 2010 Nov; 75(20):1794-802. PubMed ID: 21079181 [TBL] [Abstract][Full Text] [Related]
30. Pregnancy and Family Planning in Multiple Sclerosis. Langer-Gould AM Continuum (Minneap Minn); 2019 Jun; 25(3):773-792. PubMed ID: 31162316 [TBL] [Abstract][Full Text] [Related]
31. Pregnancy outcome of first trimester exposure to the vitamin K antagonist phenprocoumon depends on duration of treatment. Hüttel E; Padberg S; Meister R; Beck E; Schaefer C Thromb Haemost; 2017 May; 117(5):870-879. PubMed ID: 28229160 [TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Weber-Schoendorfer C; Schaefer C Mult Scler; 2009 Sep; 15(9):1037-42. PubMed ID: 19692433 [TBL] [Abstract][Full Text] [Related]
34. Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion. Sheehy O; Zhao JP; Bérard A JAMA Psychiatry; 2019 Sep; 76(9):948-957. PubMed ID: 31090881 [TBL] [Abstract][Full Text] [Related]
35. Myocardial infarction in a patient with multiple sclerosis after receiving natalizumab. Darki A; Masoumi P; Soleimani A; Naser Moghadasi A Mult Scler Relat Disord; 2018 Oct; 25():26-28. PubMed ID: 30025371 [TBL] [Abstract][Full Text] [Related]
36. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. Lopez-Leon S; Geissbühler Y; Sabidó M; Turkson M; Wahlich C; Morris JK J Neurol; 2020 Sep; 267(9):2721-2731. PubMed ID: 32444984 [TBL] [Abstract][Full Text] [Related]
37. How safe is natalizumab during pregnancy? Duquette P; Prat A Mult Scler; 2015 Feb; 21(2):121-2. PubMed ID: 25392323 [No Abstract] [Full Text] [Related]
38. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO. Enzinger C Mult Scler; 2017 May; 23(6):767-770. PubMed ID: 28287038 [No Abstract] [Full Text] [Related]
39. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. Guilloton L; Pegat A; Defrance J; Quesnel L; Barral G; Drouet A J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):301-302. PubMed ID: 28403930 [TBL] [Abstract][Full Text] [Related]
40. Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. Durrieu G; Dardonville Q; Clanet M; Montastruc JL Fundam Clin Pharmacol; 2019 Feb; 33(1):125-126. PubMed ID: 29935014 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]